摘要
目的探讨中晚期肝癌肝动脉化疗栓塞的疗效及影响疗效的因素。方法 5 0 8例不能切除的原发性肝癌行选择性肝动脉插管灌注化疗和栓塞治疗共 2 0 2 5次 ,其中行选择性肝动脉管灌注化疗栓塞治疗 44 8例 ,单纯灌注化疗 6 0例。结果选择性肝动脉插管灌注化疗栓塞 l、2、3年生存率分别为 81 .3%、38.6 %、2 1 .6 % ;单纯灌注化疗 1、2、3年生存率分别为 5 4.3%、2 1 .3%、9.6 %。肿瘤分类、栓塞剂及用量、门静脉是否有癌栓、侧支循环的形成、碘油沉积情况及栓塞技术和方法选择是否得当是影响疗效的主要因素。结论选择性肝动脉插管灌注化疗栓塞可作为中晚期肝癌的常规治疗 。
ObjectiveTo evaluate the therapeutic efficacy of hepatic arterial chemoembolization (HACE) and factors influencing efficacy.Methods2025 selective transcatheter arterial perfusion chemotherapy (TAPC) and embolization therapy were performed in 508 unresectable primary hepatocarcinoma,448 of whom received selective TAPC and 60 of whom received transcatheter arterial perfusion chemotherapy (TAPC) alone.ResultsThe survival rates at 1,2 and 3 year of HACE were 81.3%,38.6% and 21.6%,respectively,while,the survival rates at 1,2 and 3 year of TAPC were 54.3%,21.3% and 9.6%,respectively.The main factors influencing therapeutic effect were the typing of tumor,embolizing agents and their dosage,the portal infiltration,the formation of collateral circulation,accumulation of iodized oil and the embolizing technique and measurements.ConclusionHACE can be used routinely for treating advanced hepatocarcinoma,which long term efficacy is better than TAPC.
出处
《中国综合临床》
北大核心
2002年第7期632-633,共2页
Clinical Medicine of China
关键词
肝癌
肝动脉
栓塞
化疗
Hepatocarcinoma
Hepatic artery
Embolization
Chemotherapy
